{"product_id":"s4andarine-50x50mg","title":"S4(Andarine) 100x50mg","description":"\u003cp\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                         \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003eFOR HUMAN \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eCONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eS4 \u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003e(Andarine, GTx-007) is a \u003cstrong data-start=\"120\" data-end=\"181\"\u003enonsteroidal selective androgen receptor modulator (SARM)\u003c\/strong\u003e developed by GTx for \u003cstrong data-start=\"203\" data-end=\"275\"\u003eosteoporosis, muscle wasting, and benign prostatic hyperplasia (BPH)\u003c\/strong\u003e. It binds the \u003cstrong data-start=\"290\" data-end=\"316\"\u003eandrogen receptor (AR)\u003c\/strong\u003e with tissue-selective, \u003cstrong data-start=\"340\" data-end=\"359\"\u003epartial agonist\u003c\/strong\u003e activity—aiming to \u003cstrong data-start=\"379\" data-end=\"408\"\u003estimulate bone and muscle\u003c\/strong\u003e while \u003cstrong data-start=\"415\" data-end=\"454\"\u003esparing prostate and hair follicles\u003c\/strong\u003e relative to testosterone\/DHT. Clinical development never reached approval; most human data are \u003cstrong data-start=\"550\" data-end=\"565\"\u003eearly-phase\u003c\/strong\u003e. It is \u003cstrong data-start=\"573\" data-end=\"589\"\u003enot approved\u003c\/strong\u003e for any indication and is \u003cstrong data-start=\"616\" data-end=\"638\"\u003eprohibited by WADA\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-start=\"641\" data-end=\"644\"\u003e\n\u003ch3 data-start=\"646\" data-end=\"700\"\u003eAdditional Benefits of S-4 Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"702\" data-end=\"2630\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"702\" data-end=\"730\"\u003e\n\u003ctr data-start=\"702\" data-end=\"730\"\u003e\n\u003cth data-start=\"702\" data-end=\"712\" data-col-size=\"sm\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"712\" data-end=\"730\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"741\" data-end=\"2630\"\u003e\n\u003ctr data-start=\"741\" data-end=\"1006\"\u003e\n\u003ctd data-start=\"741\" data-end=\"772\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"743\" data-end=\"771\"\u003e1 Lean mass preservation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"772\" data-end=\"1006\" data-col-size=\"xl\"\u003eIn animal and early human studies, S-4 increases \u003cstrong data-start=\"823\" data-end=\"841\"\u003elean body mass\u003c\/strong\u003e and \u003cstrong data-start=\"846\" data-end=\"865\"\u003emuscle strength\u003c\/strong\u003e or preserves them during \u003cstrong data-start=\"891\" data-end=\"926\"\u003ehypogonadism or caloric deficit\u003c\/strong\u003e, with less virilization than anabolic steroids at comparable anabolic effect.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1007\" data-end=\"1239\"\u003e\n\u003ctd data-start=\"1007\" data-end=\"1036\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1009\" data-end=\"1035\"\u003e2 Bone-density support\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1036\" data-end=\"1239\" data-col-size=\"xl\"\u003eS-4 improves \u003cstrong data-start=\"1051\" data-end=\"1081\"\u003ebone mineral density (BMD)\u003c\/strong\u003e and \u003cstrong data-start=\"1086\" data-end=\"1112\"\u003ebiomechanical strength\u003c\/strong\u003e in osteopenic\/ovariectomized models, mimicking some of testosterone’s skeletal benefits without strong prostate stimulation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1240\" data-end=\"1480\"\u003e\n\u003ctd data-start=\"1240\" data-end=\"1281\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1242\" data-end=\"1280\"\u003e3 Prostate-sparing androgen action\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1281\" data-end=\"1480\" data-col-size=\"xl\"\u003eIn castrated rodent models, S-4 \u003cstrong data-start=\"1315\" data-end=\"1339\"\u003esupports muscle\/bone\u003c\/strong\u003e while causing \u003cstrong data-start=\"1354\" data-end=\"1383\"\u003eless prostate enlargement\u003c\/strong\u003ethan DHT and even \u003cstrong data-start=\"1402\" data-end=\"1429\"\u003ereduces prostate weight\u003c\/strong\u003e under some conditions—basis for its BPH program.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1481\" data-end=\"1674\"\u003e\n\u003ctd data-start=\"1481\" data-end=\"1512\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1483\" data-end=\"1511\"\u003e4 Functional performance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1512\" data-end=\"1674\" data-col-size=\"xl\"\u003ePreclinical work shows \u003cstrong data-start=\"1537\" data-end=\"1611\"\u003eincreased grip strength, running time, and muscle cross-sectional area\u003c\/strong\u003e, indicating true functional gains, not just water retention.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1675\" data-end=\"1876\"\u003e\n\u003ctd data-start=\"1675\" data-end=\"1715\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1677\" data-end=\"1714\"\u003e5 Potential cachexia applications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1715\" data-end=\"1876\" data-col-size=\"xl\"\u003eThe combination of \u003cstrong data-start=\"1736\" data-end=\"1767\"\u003eanabolic and anti-catabolic\u003c\/strong\u003e actions suggests utility for \u003cstrong data-start=\"1797\" data-end=\"1832\"\u003ecancer\/illness-related cachexia\u003c\/strong\u003e; this remains theoretical and unapproved.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1877\" data-end=\"2006\"\u003e\n\u003ctd data-start=\"1877\" data-end=\"1899\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1879\" data-end=\"1898\"\u003e6 Oral delivery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1899\" data-end=\"2006\" data-col-size=\"xl\"\u003eS-4 is \u003cstrong data-start=\"1908\" data-end=\"1931\"\u003eorally bioavailable\u003c\/strong\u003e, avoiding injections and allowing once- or twice-daily dosing in trials.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2007\" data-end=\"2220\"\u003e\n\u003ctd data-start=\"2007\" data-end=\"2037\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2009\" data-end=\"2036\"\u003e7 Lower androgenic load\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2037\" data-end=\"2220\" data-col-size=\"xl\"\u003eCompared to full AR agonists, S-4’s \u003cstrong data-start=\"2075\" data-end=\"2094\"\u003epartial agonism\u003c\/strong\u003e and tissue selectivity lead to \u003cstrong data-start=\"2126\" data-end=\"2179\"\u003eless virilization, acne, and prostate stimulation\u003c\/strong\u003e at anabolic doses in preclinical work.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2221\" data-end=\"2413\"\u003e\n\u003ctd data-start=\"2221\" data-end=\"2251\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2223\" data-end=\"2250\"\u003e8 Limited aromatization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2251\" data-end=\"2413\" data-col-size=\"xl\"\u003eBeing nonsteroidal, it does \u003cstrong data-start=\"2281\" data-end=\"2311\"\u003enot aromatize to estradiol\u003c\/strong\u003e or reduce 5-α reductase; E2 shifts are secondary (via HPT-axis suppression), not direct conversion.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2414\" data-end=\"2630\"\u003e\n\u003ctd data-start=\"2414\" data-end=\"2459\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2416\" data-end=\"2458\"\u003e9 Conceptual stacking with other SARMs\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2459\" data-end=\"2630\" data-col-size=\"xl\"\u003eIn research, S-4 has been explored as a \u003cstrong data-start=\"2501\" data-end=\"2525\"\u003ebone-\/cutting-biased\u003c\/strong\u003e SARM alongside more potent anabolic SARMs; this is entirely experimental and not clinically validated.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"2632\" data-end=\"2635\"\u003e\n\u003ch2 data-start=\"2637\" data-end=\"2672\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"2674\" data-end=\"2709\"\u003e2.1 Receptor pharmacodynamics\u003c\/h3\u003e\n\u003cul data-start=\"2711\" data-end=\"3246\"\u003e\n\u003cli data-start=\"2711\" data-end=\"2876\"\u003e\n\u003cp data-start=\"2713\" data-end=\"2876\"\u003e\u003cstrong data-start=\"2713\" data-end=\"2724\"\u003eTarget:\u003c\/strong\u003e Andarine binds the \u003cstrong data-start=\"2744\" data-end=\"2770\"\u003eandrogen receptor (AR)\u003c\/strong\u003e as a \u003cstrong data-start=\"2776\" data-end=\"2795\"\u003epartial agonist\u003c\/strong\u003e with a distinct co-activator recruitment profile compared to DHT\/testosterone.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2877\" data-end=\"3246\"\u003e\n\u003cp data-start=\"2879\" data-end=\"2904\"\u003e\u003cstrong data-start=\"2879\" data-end=\"2902\"\u003eTissue selectivity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"2907\" data-end=\"3246\"\u003e\n\u003cli data-start=\"2907\" data-end=\"3063\"\u003e\n\u003cp data-start=\"2909\" data-end=\"3063\"\u003e\u003cstrong data-start=\"2909\" data-end=\"2936\"\u003eSkeletal muscle \u0026amp; bone:\u003c\/strong\u003e Acts more like an \u003cstrong data-start=\"2955\" data-end=\"2966\"\u003eagonist\u003c\/strong\u003e, promoting \u003cstrong data-start=\"2978\" data-end=\"2999\"\u003eprotein synthesis\u003c\/strong\u003e, \u003cstrong data-start=\"3001\" data-end=\"3019\"\u003eantiresorptive\u003c\/strong\u003e signaling, and \u003cstrong data-start=\"3035\" data-end=\"3060\"\u003eosteoblastic activity\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3066\" data-end=\"3246\"\u003e\n\u003cp data-start=\"3068\" data-end=\"3246\"\u003e\u003cstrong data-start=\"3068\" data-end=\"3104\"\u003eProstate \u0026amp; reproductive tissues:\u003c\/strong\u003e Behaves \u003cstrong data-start=\"3113\" data-end=\"3130\"\u003eless strongly\u003c\/strong\u003e than DHT; in some models, functions almost as a \u003cstrong data-start=\"3179\" data-end=\"3204\"\u003efunctional antagonist\u003c\/strong\u003e by competing with endogenous androgens.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3248\" data-end=\"3275\"\u003e2.2 Down-stream biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3277\" data-end=\"3703\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3277\" data-end=\"3319\"\u003e\n\u003ctr data-start=\"3277\" data-end=\"3319\"\u003e\n\u003cth data-start=\"3277\" data-end=\"3287\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3287\" data-end=\"3308\" data-col-size=\"md\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3308\" data-end=\"3319\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3334\" data-end=\"3703\"\u003e\n\u003ctr data-start=\"3334\" data-end=\"3430\"\u003e\n\u003ctd data-start=\"3334\" data-end=\"3361\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3336\" data-end=\"3360\"\u003eAR–ARE transcription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3361\" data-end=\"3411\" data-col-size=\"md\"\u003e↑ Myofibrillar protein synthesis, ↓ proteolysis\u003c\/td\u003e\n\u003ctd data-start=\"3411\" data-end=\"3430\" data-col-size=\"sm\"\u003eSkeletal muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3431\" data-end=\"3510\"\u003e\n\u003ctd data-start=\"3431\" data-end=\"3477\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3433\" data-end=\"3476\"\u003eRANKL\/OPG balance \u0026amp; osteoblast activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3477\" data-end=\"3502\" data-col-size=\"md\"\u003e↑ BMD, ↑ bone strength\u003c\/td\u003e\n\u003ctd data-start=\"3502\" data-end=\"3510\" data-col-size=\"sm\"\u003eBone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3511\" data-end=\"3611\"\u003e\n\u003ctd data-start=\"3511\" data-end=\"3545\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3513\" data-end=\"3544\"\u003eProstate AR partial agonism\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3545\" data-end=\"3597\" data-col-size=\"md\"\u003e↓ Prostate weight vs DHT at equal anabolic effect\u003c\/td\u003e\n\u003ctd data-start=\"3597\" data-end=\"3611\" data-col-size=\"sm\"\u003eBPH models\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3612\" data-end=\"3703\"\u003e\n\u003ctd data-start=\"3612\" data-end=\"3636\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3614\" data-end=\"3635\"\u003eHPT-axis feedback\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3636\" data-end=\"3681\" data-col-size=\"md\"\u003e↓ LH\/FSH → ↓ endogenous T with chronic use\u003c\/td\u003e\n\u003ctd data-start=\"3681\" data-end=\"3703\" data-col-size=\"sm\"\u003eSystemic endocrine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3705\" data-end=\"3708\"\u003e\n\u003ch2 data-start=\"3710\" data-end=\"3772\"\u003e3. Pharmacokinetics (from early studies \u0026amp; preclinical data)\u003c\/h2\u003e\n\u003cul data-start=\"3774\" data-end=\"4280\"\u003e\n\u003cli data-start=\"3774\" data-end=\"3839\"\u003e\n\u003cp data-start=\"3776\" data-end=\"3839\"\u003e\u003cstrong data-start=\"3776\" data-end=\"3786\"\u003eRoute:\u003c\/strong\u003e \u003cstrong data-start=\"3787\" data-end=\"3795\"\u003eOral\u003c\/strong\u003e, typically once or twice daily in trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3840\" data-end=\"3954\"\u003e\n\u003cp data-start=\"3842\" data-end=\"3954\"\u003e\u003cstrong data-start=\"3842\" data-end=\"3856\"\u003eHalf-life:\u003c\/strong\u003e On the order of \u003cstrong data-start=\"3873\" data-end=\"3899\"\u003ehours (short–moderate)\u003c\/strong\u003e; supports BID dosing in many experimental protocols.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3955\" data-end=\"4013\"\u003e\n\u003cp data-start=\"3957\" data-end=\"4013\"\u003e\u003cstrong data-start=\"3957\" data-end=\"3972\"\u003eAbsorption:\u003c\/strong\u003e Good oral bioavailability; lipophilic.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4014\" data-end=\"4124\"\u003e\n\u003cp data-start=\"4016\" data-end=\"4124\"\u003e\u003cstrong data-start=\"4016\" data-end=\"4033\"\u003eDistribution:\u003c\/strong\u003e Binds AR in muscle, bone, prostate, and other AR-rich tissues; crosses into many organs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4125\" data-end=\"4219\"\u003e\n\u003cp data-start=\"4127\" data-end=\"4219\"\u003e\u003cstrong data-start=\"4127\" data-end=\"4142\"\u003eMetabolism:\u003c\/strong\u003e Hepatic metabolic clearance; exact CYP profile not publicly characterized.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4220\" data-end=\"4280\"\u003e\n\u003cp data-start=\"4222\" data-end=\"4280\"\u003e\u003cstrong data-start=\"4222\" data-end=\"4236\"\u003eExcretion:\u003c\/strong\u003e Primarily renal and biliary as metabolites.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4282\" data-end=\"4285\"\u003e\n\u003ch2 data-start=\"4287\" data-end=\"4325\"\u003e4. Pre-clinical \u0026amp; Clinical Evidence\u003c\/h2\u003e\n\u003cul data-start=\"4327\" data-end=\"4920\"\u003e\n\u003cli data-start=\"4327\" data-end=\"4488\"\u003e\n\u003cp data-start=\"4329\" data-end=\"4488\"\u003e\u003cstrong data-start=\"4329\" data-end=\"4358\"\u003eOsteoporosis\/Bone models:\u003c\/strong\u003e S-4 restored \u003cstrong data-start=\"4372\" data-end=\"4397\"\u003eBMD and bone strength\u003c\/strong\u003e in ovariectomized rats while keeping \u003cstrong data-start=\"4435\" data-end=\"4467\"\u003eprostate size relatively low\u003c\/strong\u003e compared with DHT.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4489\" data-end=\"4683\"\u003e\n\u003cp data-start=\"4491\" data-end=\"4683\"\u003e\u003cstrong data-start=\"4491\" data-end=\"4530\"\u003eMuscle wasting\/hypogonadism models:\u003c\/strong\u003e Improved \u003cstrong data-start=\"4540\" data-end=\"4566\"\u003elean mass and strength\u003c\/strong\u003e, outperforming placebo and approaching low-dose testosterone’s anabolic effect with less androgenic tissue impact.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4684\" data-end=\"4920\"\u003e\n\u003cp data-start=\"4686\" data-end=\"4920\"\u003e\u003cstrong data-start=\"4686\" data-end=\"4724\"\u003eBPH\/androgen-deprivation settings:\u003c\/strong\u003e Showed ability to \u003cstrong data-start=\"4743\" data-end=\"4767\"\u003emaintain muscle\/bone\u003c\/strong\u003e under androgen deprivation while \u003cstrong data-start=\"4801\" data-end=\"4841\"\u003enot excessively stimulating prostate\u003c\/strong\u003e, making it attractive in theory as an adjunct to androgen-deprivation therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-start=\"4922\" data-end=\"5176\"\u003e\n\u003cp data-start=\"4924\" data-end=\"5176\"\u003e\u003cstrong data-start=\"4924\" data-end=\"4950\"\u003eEvidence quality note:\u003c\/strong\u003e Most data are \u003cstrong data-start=\"4965\" data-end=\"4983\"\u003eanimal studies\u003c\/strong\u003e plus \u003cstrong data-start=\"4989\" data-end=\"5024\"\u003esmall, early-phase human trials\u003c\/strong\u003e. There are \u003cstrong data-start=\"5036\" data-end=\"5061\"\u003eno large Phase 3 data\u003c\/strong\u003e, no approved indications, and the full risk–benefit profile at therapeutic doses remains \u003cstrong data-start=\"5151\" data-end=\"5175\"\u003eincompletely defined\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"5178\" data-end=\"5181\"\u003e\n\u003ch2 data-start=\"5183\" data-end=\"5229\"\u003e5. Emerging Clinical Interests (conceptual)\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"5231\" data-end=\"5771\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"5231\" data-end=\"5261\"\u003e\n\u003ctr data-start=\"5231\" data-end=\"5261\"\u003e\n\u003cth data-start=\"5231\" data-end=\"5239\" data-col-size=\"md\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"5239\" data-end=\"5251\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"5251\" data-end=\"5261\" data-col-size=\"sm\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"5276\" data-end=\"5771\"\u003e\n\u003ctr data-start=\"5276\" data-end=\"5378\"\u003e\n\u003ctd data-start=\"5276\" data-end=\"5313\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"5278\" data-end=\"5312\"\u003eMale osteoporosis \/ osteopenia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5313\" data-end=\"5348\" data-col-size=\"md\"\u003eBone-anabolic + prostate-sparing\u003c\/td\u003e\n\u003ctd data-start=\"5348\" data-end=\"5378\" data-col-size=\"sm\"\u003ePreclinical\/early clinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5379\" data-end=\"5465\"\u003e\n\u003ctd data-start=\"5379\" data-end=\"5406\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"5381\" data-end=\"5405\"\u003eSarcopenia \/ frailty\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5406\" data-end=\"5454\" data-col-size=\"md\"\u003eMuscle maintenance with lower androgenic load\u003c\/td\u003e\n\u003ctd data-start=\"5454\" data-end=\"5465\" data-col-size=\"sm\"\u003eConcept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5466\" data-end=\"5553\"\u003e\n\u003ctd data-start=\"5466\" data-end=\"5498\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"5468\" data-end=\"5497\"\u003eCachexia (cancer\/HIV\/CHF)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5498\" data-end=\"5530\" data-col-size=\"md\"\u003eAnticatabolic, oral, anabolic\u003c\/td\u003e\n\u003ctd data-start=\"5530\" data-end=\"5553\" data-col-size=\"sm\"\u003ePreclinical concept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5554\" data-end=\"5670\"\u003e\n\u003ctd data-start=\"5554\" data-end=\"5606\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"5556\" data-end=\"5605\"\u003eAdjunct in androgen-deprivation (prostate CA)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5606\" data-end=\"5643\" data-col-size=\"md\"\u003ePreserve muscle\/bone, not prostate\u003c\/td\u003e\n\u003ctd data-start=\"5643\" data-end=\"5670\" data-col-size=\"sm\"\u003eConcept; safety complex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5671\" data-end=\"5771\"\u003e\n\u003ctd data-start=\"5671\" data-end=\"5715\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"5673\" data-end=\"5714\"\u003eFemale osteoporosis (post-menopausal)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5715\" data-end=\"5751\" data-col-size=\"md\"\u003eBone support without virilization\u003c\/td\u003e\n\u003ctd data-start=\"5751\" data-end=\"5771\" data-col-size=\"sm\"\u003eAnimal data only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"5773\" data-end=\"5776\"\u003e\n\u003ch2 data-start=\"5778\" data-end=\"5807\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cp data-start=\"5809\" data-end=\"5960\"\u003e\u003cstrong data-start=\"5809\" data-end=\"5823\"\u003eImportant:\u003c\/strong\u003e Much of the human safety profile is inferred from \u003cstrong data-start=\"5874\" data-end=\"5896\"\u003elimited trial data\u003c\/strong\u003e and \u003cstrong data-start=\"5901\" data-end=\"5930\"\u003eoff-label\/grey-market use\u003c\/strong\u003e, not long, high-quality RCTs.\u003c\/p\u003e\n\u003ch3 data-start=\"5962\" data-end=\"5998\"\u003e6.1 Commonly reported \/ expected\u003c\/h3\u003e\n\u003cul data-start=\"6000\" data-end=\"6957\"\u003e\n\u003cli data-start=\"6000\" data-end=\"6350\"\u003e\n\u003cp data-start=\"6002\" data-end=\"6046\"\u003e\u003cstrong data-start=\"6002\" data-end=\"6044\"\u003eVisual disturbances (hallmark of S-4):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"6049\" data-end=\"6350\"\u003e\n\u003cli data-start=\"6049\" data-end=\"6107\"\u003e\n\u003cp data-start=\"6051\" data-end=\"6107\"\u003e\u003cstrong data-start=\"6051\" data-end=\"6066\"\u003eYellow tint\u003c\/strong\u003e to vision or altered color perception.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6110\" data-end=\"6176\"\u003e\n\u003cp data-start=\"6112\" data-end=\"6176\"\u003e\u003cstrong data-start=\"6112\" data-end=\"6139\"\u003eNight-vision difficulty\u003c\/strong\u003e (reduced adaptation in low light).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6179\" data-end=\"6350\"\u003e\n\u003cp data-start=\"6181\" data-end=\"6350\"\u003eUsually dose-related and reversible after discontinuation in reports; likely due to S-4 or its metabolites affecting \u003cstrong data-start=\"6298\" data-end=\"6319\"\u003eretinal signaling\u003c\/strong\u003e (exact mechanism uncertain).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6351\" data-end=\"6554\"\u003e\n\u003cp data-start=\"6353\" data-end=\"6381\"\u003e\u003cstrong data-start=\"6353\" data-end=\"6379\"\u003eEndocrine suppression:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"6384\" data-end=\"6554\"\u003e\n\u003cli data-start=\"6384\" data-end=\"6466\"\u003e\n\u003cp data-start=\"6386\" data-end=\"6466\"\u003eDecreased \u003cstrong data-start=\"6396\" data-end=\"6406\"\u003eLH\/FSH\u003c\/strong\u003e, \u003cstrong data-start=\"6408\" data-end=\"6439\"\u003etotal and free testosterone\u003c\/strong\u003e with prolonged exposure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6469\" data-end=\"6554\"\u003e\n\u003cp data-start=\"6471\" data-end=\"6554\"\u003ePotential \u003cstrong data-start=\"6481\" data-end=\"6503\"\u003etesticular atrophy\u003c\/strong\u003e and transient \u003cstrong data-start=\"6518\" data-end=\"6534\"\u003esubfertility\u003c\/strong\u003e with chronic use.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6555\" data-end=\"6732\"\u003e\n\u003cp data-start=\"6557\" data-end=\"6732\"\u003e\u003cstrong data-start=\"6557\" data-end=\"6577\"\u003eAndrogenic\/skin:\u003c\/strong\u003e Mild \u003cstrong data-start=\"6583\" data-end=\"6591\"\u003eacne\u003c\/strong\u003e, \u003cstrong data-start=\"6593\" data-end=\"6606\"\u003eoily skin\u003c\/strong\u003e, \u003cstrong data-start=\"6608\" data-end=\"6625\"\u003ehair shedding\u003c\/strong\u003e in susceptible individuals—generally milder than full androgenic steroids at equivalent anabolic effect.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6733\" data-end=\"6827\"\u003e\n\u003cp data-start=\"6735\" data-end=\"6827\"\u003e\u003cstrong data-start=\"6735\" data-end=\"6746\"\u003eLipids:\u003c\/strong\u003e \u003cstrong data-start=\"6747\" data-end=\"6764\"\u003eHDL reduction\u003c\/strong\u003e and possible \u003cstrong data-start=\"6778\" data-end=\"6794\"\u003eLDL increase\u003c\/strong\u003e, as with many androgens\/SARMs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6828\" data-end=\"6957\"\u003e\n\u003cp data-start=\"6830\" data-end=\"6957\"\u003e\u003cstrong data-start=\"6830\" data-end=\"6840\"\u003eLiver:\u003c\/strong\u003e Mild \u003cstrong data-start=\"6846\" data-end=\"6868\"\u003eALT\/AST elevations\u003c\/strong\u003e reported anecdotally; robust hepatotoxicity data are lacking but caution is appropriate.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"6959\" data-end=\"6992\"\u003e6.2 Less common \/ theoretical\u003c\/h3\u003e\n\u003cul data-start=\"6994\" data-end=\"7570\"\u003e\n\u003cli data-start=\"6994\" data-end=\"7114\"\u003e\n\u003cp data-start=\"6996\" data-end=\"7114\"\u003e\u003cstrong data-start=\"6996\" data-end=\"7016\"\u003eCardiometabolic:\u003c\/strong\u003e Possible \u003cstrong data-start=\"7026\" data-end=\"7042\"\u003eBP increases\u003c\/strong\u003e, \u003cstrong data-start=\"7044\" data-end=\"7064\"\u003ehematocrit drift\u003c\/strong\u003e, and unknown long-term \u003cstrong data-start=\"7088\" data-end=\"7111\"\u003ecardiovascular risk\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7115\" data-end=\"7241\"\u003e\n\u003cp data-start=\"7117\" data-end=\"7241\"\u003e\u003cstrong data-start=\"7117\" data-end=\"7137\"\u003eMood\/neurologic:\u003c\/strong\u003e Some users report \u003cstrong data-start=\"7156\" data-end=\"7190\"\u003eirritability, decreased libido\u003c\/strong\u003e with endogenous suppression; data are anecdotal.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7242\" data-end=\"7394\"\u003e\n\u003cp data-start=\"7244\" data-end=\"7394\"\u003e\u003cstrong data-start=\"7244\" data-end=\"7261\"\u003eReproductive:\u003c\/strong\u003e Potential impact on \u003cstrong data-start=\"7282\" data-end=\"7301\"\u003espermatogenesis\u003c\/strong\u003e and fertility with long-term use; recovery time after cessation is not well characterized.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7395\" data-end=\"7570\"\u003e\n\u003cp data-start=\"7397\" data-end=\"7570\"\u003e\u003cstrong data-start=\"7397\" data-end=\"7410\"\u003eOncology:\u003c\/strong\u003e Long-term \u003cstrong data-start=\"7421\" data-end=\"7435\"\u003etumor risk\u003c\/strong\u003e with chronic partial AR stimulation\/inhibition has not been mapped; caution in anyone with a history of \u003cstrong data-start=\"7540\" data-end=\"7569\"\u003ehormone-sensitive cancers\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"7572\" data-end=\"7606\"\u003e6.3 Anti-doping \/ legal status\u003c\/h3\u003e\n\u003cul data-start=\"7608\" data-end=\"7933\"\u003e\n\u003cli data-start=\"7608\" data-end=\"7712\"\u003e\n\u003cp data-start=\"7610\" data-end=\"7712\"\u003e\u003cstrong data-start=\"7610\" data-end=\"7619\"\u003eWADA:\u003c\/strong\u003e SARMs (including \u003cstrong data-start=\"7637\" data-end=\"7653\"\u003eS-4\/Andarine\u003c\/strong\u003e) are \u003cstrong data-start=\"7659\" data-end=\"7686\"\u003eprohibited at all times\u003c\/strong\u003e (S1.2 anabolic agents).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7713\" data-end=\"7933\"\u003e\n\u003cp data-start=\"7715\" data-end=\"7933\"\u003e\u003cstrong data-start=\"7715\" data-end=\"7730\"\u003eRegulation:\u003c\/strong\u003e S-4 is \u003cstrong data-start=\"7738\" data-end=\"7768\"\u003enot an approved medication\u003c\/strong\u003e; many jurisdictions treat SARMs sold for human consumption as \u003cstrong data-start=\"7831\" data-end=\"7857\"\u003eunlawful or controlled\u003c\/strong\u003e. Grey-market powders\/capsules often have \u003cstrong data-start=\"7899\" data-end=\"7932\"\u003emislabeling and contamination\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7935\" data-end=\"7938\"\u003e\n\u003ch2 data-start=\"7940\" data-end=\"7986\"\u003e7. Comparative Snapshot (SARMs \u0026amp; anabolics)\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"7988\" data-end=\"8655\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"7988\" data-end=\"8098\"\u003e\n\u003ctr data-start=\"7988\" data-end=\"8098\"\u003e\n\u003cth data-start=\"7988\" data-end=\"7998\" data-col-size=\"sm\"\u003eFeature\u003c\/th\u003e\n\u003cth data-start=\"7998\" data-end=\"8019\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"8000\" data-end=\"8018\"\u003eS-4 (Andarine)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"8019\" data-end=\"8046\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"8021\" data-end=\"8045\"\u003eLGD-4033 (Ligandrol)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"8046\" data-end=\"8072\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"8048\" data-end=\"8071\"\u003eRAD-140 (Testolone)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"8072\" data-end=\"8098\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"8074\" data-end=\"8096\"\u003eTestosterone (TRT)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"8121\" data-end=\"8655\"\u003e\n\u003ctr data-start=\"8121\" data-end=\"8239\"\u003e\n\u003ctd data-start=\"8121\" data-end=\"8134\" data-col-size=\"sm\"\u003eAR profile\u003c\/td\u003e\n\u003ctd data-start=\"8134\" data-end=\"8174\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"8136\" data-end=\"8173\"\u003ePartial agonist, tissue-selective\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"8174\" data-end=\"8194\" data-col-size=\"sm\"\u003ePotent AR agonist\u003c\/td\u003e\n\u003ctd data-start=\"8194\" data-end=\"8223\" data-col-size=\"sm\"\u003ePotent, somewhat selective\u003c\/td\u003e\n\u003ctd data-start=\"8223\" data-end=\"8239\" data-col-size=\"sm\"\u003eFull agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"8240\" data-end=\"8296\"\u003e\n\u003ctd data-start=\"8240\" data-end=\"8253\" data-col-size=\"sm\"\u003eBone focus\u003c\/td\u003e\n\u003ctd data-start=\"8253\" data-end=\"8266\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"8255\" data-end=\"8265\"\u003eStrong\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"8266\" data-end=\"8275\" data-col-size=\"sm\"\u003eStrong\u003c\/td\u003e\n\u003ctd data-start=\"8275\" data-end=\"8286\" data-col-size=\"sm\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-start=\"8286\" data-end=\"8296\" data-col-size=\"sm\"\u003eStrong\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"8297\" data-end=\"8381\"\u003e\n\u003ctd data-start=\"8297\" data-end=\"8320\" data-col-size=\"sm\"\u003eProstate stimulation\u003c\/td\u003e\n\u003ctd data-start=\"8320\" data-end=\"8345\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"8322\" data-end=\"8344\"\u003eLower; sometimes ↓\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"8345\" data-end=\"8356\" data-col-size=\"sm\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-start=\"8356\" data-end=\"8367\" data-col-size=\"sm\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-start=\"8367\" data-end=\"8381\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"8369\" data-end=\"8379\"\u003eHigher\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"8382\" data-end=\"8469\"\u003e\n\u003ctd data-start=\"8382\" data-end=\"8395\" data-col-size=\"sm\"\u003eVision AEs\u003c\/td\u003e\n\u003ctd data-start=\"8395\" data-end=\"8431\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"8397\" data-end=\"8430\"\u003eCharacteristic (night\/yellow)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"8431\" data-end=\"8446\" data-col-size=\"sm\"\u003eNone typical\u003c\/td\u003e\n\u003ctd data-start=\"8446\" data-end=\"8461\" data-col-size=\"sm\"\u003eNone typical\u003c\/td\u003e\n\u003ctd data-start=\"8461\" data-end=\"8469\" data-col-size=\"sm\"\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"8470\" data-end=\"8546\"\u003e\n\u003ctd data-start=\"8470\" data-end=\"8488\" data-col-size=\"sm\"\u003eHPT suppression\u003c\/td\u003e\n\u003ctd data-start=\"8488\" data-end=\"8509\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"8490\" data-end=\"8508\"\u003eYes (moderate)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"8509\" data-end=\"8524\" data-col-size=\"sm\"\u003eYes (strong)\u003c\/td\u003e\n\u003ctd data-start=\"8524\" data-end=\"8539\" data-col-size=\"sm\"\u003eYes (strong)\u003c\/td\u003e\n\u003ctd data-start=\"8539\" data-end=\"8546\" data-col-size=\"sm\"\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"8547\" data-end=\"8655\"\u003e\n\u003ctd data-start=\"8547\" data-end=\"8564\" data-col-size=\"sm\"\u003eLegal\/approval\u003c\/td\u003e\n\u003ctd data-start=\"8564\" data-end=\"8591\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"8566\" data-end=\"8590\"\u003eUnapproved, SARM ban\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"8591\" data-end=\"8614\" data-col-size=\"sm\"\u003eUnapproved, SARM ban\u003c\/td\u003e\n\u003ctd data-start=\"8614\" data-end=\"8637\" data-col-size=\"sm\"\u003eUnapproved, SARM ban\u003c\/td\u003e\n\u003ctd data-start=\"8637\" data-end=\"8655\" data-col-size=\"sm\"\u003eApproved (TRT)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"8657\" data-end=\"8660\"\u003e\n\u003ch2 data-start=\"8662\" data-end=\"8688\"\u003e8. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"8690\" data-end=\"8993\"\u003e\n\u003cli data-start=\"8690\" data-end=\"8742\"\u003e\n\u003cp data-start=\"8692\" data-end=\"8742\"\u003e\u003cstrong data-start=\"8692\" data-end=\"8708\"\u003eNo approvals\u003c\/strong\u003e in US\/EU\/UK\/most jurisdictions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8743\" data-end=\"8875\"\u003e\n\u003cp data-start=\"8745\" data-end=\"8875\"\u003eUsed only in \u003cstrong data-start=\"8758\" data-end=\"8770\"\u003eresearch\u003c\/strong\u003e; any therapeutic development has \u003cstrong data-start=\"8804\" data-end=\"8815\"\u003estalled\u003c\/strong\u003e in favor of newer SARMs or different anabolic approaches.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8876\" data-end=\"8993\"\u003e\n\u003cp data-start=\"8878\" data-end=\"8993\"\u003eWidely sold online as a \u003cstrong data-start=\"8902\" data-end=\"8923\"\u003eresearch chemical\u003c\/strong\u003e, often in \u003cstrong data-start=\"8934\" data-end=\"8945\"\u003enon-GMP\u003c\/strong\u003e conditions with \u003cstrong data-start=\"8962\" data-end=\"8992\"\u003eunverified purity and dose\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"8995\" data-end=\"8998\"\u003e\n\u003ch2 data-start=\"9000\" data-end=\"9040\"\u003e9. Practical Take \u0026amp; Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"9042\" data-end=\"9697\"\u003e\n\u003cli data-start=\"9042\" data-end=\"9157\"\u003e\n\u003cp data-start=\"9044\" data-end=\"9157\"\u003e\u003cstrong data-start=\"9044\" data-end=\"9056\"\u003eFor now:\u003c\/strong\u003e S-4 is best regarded as a \u003cstrong data-start=\"9083\" data-end=\"9130\"\u003ehistorical SARM prototype and research tool\u003c\/strong\u003e, not a clinical therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9158\" data-end=\"9342\"\u003e\n\u003cp data-start=\"9160\" data-end=\"9342\"\u003e\u003cstrong data-start=\"9160\" data-end=\"9182\"\u003eMain unique point:\u003c\/strong\u003e Its \u003cstrong data-start=\"9187\" data-end=\"9231\"\u003ebone-\/muscle-anabolic + prostate-sparing\u003c\/strong\u003e profile and \u003cstrong data-start=\"9244\" data-end=\"9276\"\u003edistinct visual side effects\u003c\/strong\u003e make it mechanistically interesting but clinically problematic.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9343\" data-end=\"9697\"\u003e\n\u003cp data-start=\"9345\" data-end=\"9371\"\u003e\u003cstrong data-start=\"9345\" data-end=\"9369\"\u003eResearch priorities:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"9374\" data-end=\"9697\"\u003e\n\u003cli data-start=\"9374\" data-end=\"9461\"\u003e\n\u003cp data-start=\"9376\" data-end=\"9461\"\u003eDetailed characterization of the \u003cstrong data-start=\"9409\" data-end=\"9429\"\u003eocular mechanism\u003c\/strong\u003e and long-term retinal safety.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9464\" data-end=\"9577\"\u003e\n\u003cp data-start=\"9466\" data-end=\"9577\"\u003eDevelopment of \u003cstrong data-start=\"9481\" data-end=\"9506\"\u003enext-generation SARMs\u003c\/strong\u003e that retain S-4’s \u003cstrong data-start=\"9525\" data-end=\"9552\"\u003ebone\/muscle selectivity\u003c\/strong\u003e without vision issues.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9580\" data-end=\"9697\"\u003e\n\u003cp data-start=\"9582\" data-end=\"9697\"\u003eMore complete mapping of \u003cstrong data-start=\"9607\" data-end=\"9650\"\u003elipid, cardiovascular, and reproductive\u003c\/strong\u003e impacts of AR partial agonism vs full agonism.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684868092242,"sku":null,"price":80.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/s4_50mg.png?v=1770834957","url":"https:\/\/sciencepeptideslab.com\/products\/s4andarine-50x50mg","provider":"Science Peptides Lab","version":"1.0","type":"link"}